Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PAICS | P22234 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557707 | 0.91 | DNM1 (0.43) | KDM4EDNM1ALDH1A1MAPT | |
| SCHEMBL1712655 | 0.79 | MCL1 (0.37) | KDM4ELMNAKMT2A | |
| SCHEMBL6015745 | 0.75 | KDM4E (0.46) | KDM4EUSP2MAPK1LMNADNM1 | |
| SCHEMBL1457270 | 0.75 | CCNC (0.34) | MAPT | |
| SCHEMBL6015849 | 0.72 | KDM4E (0.49) | KDM4EUSP2MAPK1LMNADNM1 | |
| SCHEMBL1712116 | 0.72 | CCNC (0.34) | ALDH1A1NPSR1 | |
| SCHEMBL3854710 | 0.69 | — | — | |
| SCHEMBL955254 | 0.69 | — | — | |
| SCHEMBL1712677 | 0.67 | — | — | |
| SCHEMBL2103703 | 0.67 | KDM4E (0.49) | KDM4EUSP2MAPK1LMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | KDM4E 1747/4885USP2 4553/4885MAPK1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.